Overview

This protocol describes a low-cost method for performing drug viability assays using patient-derived ovarian cancer organoids. It is designed to be accessible and can be applied to various organoid systems.

Key Study Components

Area of Science

Neuroscience
Oncology
Organoid Technology

Background

Patient-derived organoids are valuable for drug testing.
Traditional methods can be expensive and resource-intensive.
This protocol aims to provide a cost-effective alternative.
It can be adapted for different types of organoids.

Purpose of Study

To establish a low-cost method for drug viability assays.
To facilitate preliminary drug testing before high-throughput screening.
To enhance accessibility for research in ovarian cancer.

Methods Used

Observation of organoid confluency under a brightfield microscope.
Mechanical dissociation of organoids using a pipette.
Application of prewarmed base media to organoid wells.
Assessment of drug viability through established assays.

Main Results

The method allows for effective drug testing in organoids.
It demonstrates the feasibility of using low-cost materials.
Results can be compared to those from high-throughput screens.
Applicable to various organoid systems beyond ovarian cancer.

Conclusions

This protocol provides a practical approach for drug testing.
It supports the use of patient-derived models in research.
Future studies can build on this method for broader applications.

Frequently Asked Questions

What are ovarian cancer organoids?

Ovarian cancer organoids are 3D cultures derived from patient tumors that mimic the original tissue.

Why use a low-cost method for drug testing?

A low-cost method increases accessibility for researchers and allows preliminary testing before more expensive assays.

Can this method be applied to other types of organoids?

Yes, the protocol can be adapted for various organoid systems, including murine-derived organoids.

What materials are needed for this protocol?

The protocol utilizes low-cost and readily available materials and lab equipment.

How do you assess drug viability in organoids?

Drug viability is assessed through established assays after treatment with the drug.

What is the significance of using patient-derived organoids?

Patient-derived organoids provide a more accurate model for drug testing compared to traditional cell lines.

Institution - Washington University of Medicine in St. Louis

Articles Published in JoVE